Prosecution Insights
Last updated: April 19, 2026

Examiner: TICHY, JENNIFER M.H.

Tech Center 1600 • Art Units: 1653

This examiner grants 65% of resolved cases

Performance Statistics

65.2%
Allow Rate
+5.2% vs TC avg
683
Total Applications
+34.4%
Interview Lift
1159
Avg Prosecution Days
Based on 606 resolved cases, 2023–2026

Rejection Statute Breakdown

3.7%
§101 Eligibility
20.2%
§102 Novelty
36.0%
§103 Obviousness
29.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17906279 DESIGNER EXTRACELLULAR VESICLES FOR TREATING EXCITOTOXICITY Final Rejection OHIO STATE INNOVATION FOUNDATION
16720840 Methods and Systems for Platelet Cryopreservation Non-Final OA Fenwal, Inc.
17816924 C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS Non-Final OA THE JOHNS HOPKINS UNIVERSITY
17801959 TISSUE CULTURE MEDIA FOR SURVIVAL AND ENGRAFTMENT OF HUMAN PANCREATIC ISLETS Final Rejection THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
16753634 Tissue Engineered "Axon Fusion" for Immediate Recovery Following Axon Transection Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17521410 IDENTIFICATION OF MICROORGANISMS USING MALDI-TOF-MS ON-PLATE EXTRACTION Non-Final OA BECTON DICKINSON AND COMPANY
17566504 USE OF OVARIAN-DERIVED HYDROGELS FOR RESTORATION OF REPRODUCTIVE FUNCTION AND HEALTH IN WOMEN Non-Final OA UPMC
17789999 FIBROCARTILAGE PREPARATION METHOD USING TENSILE STIMULATION Final Rejection UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
18115402 Wearable Engineered Human Skin and Systems and Methods for Making the Same Non-Final OA The Trustees of Columbia University in the City of New York
17905088 DIBORIDE MICROPATTERNED SURFACES FOR CELL CULTURE Non-Final OA University of Houston System
18678139 Food Materials Comprising Filamentous Fungal Particles and Membrane Bioreactor Design Non-Final OA The Fynder Group, Inc.
18671703 Food Materials Comprising Filamentous Fungal Particles and Membrane Bioreactor Design Non-Final OA The Fynder Group, Inc.
17882488 Food Materials Comprising Filamentous Fungal Particles and Membrane Bioreactor Design Final Rejection The Fynder Group, Inc.
18063634 CELL CULTURE BAG Non-Final OA NAN YA PLASTICS CORPORATION
17770183 COMPOSITIONS AND METHODS FOR ENHANCING RETINAL GANGLION CELL DEVELOPMENT AND PLURIPOTENT STEM CELL-DERIVED THREE-DIMENSIONAL TISSUE Final Rejection THE TRUSTEES OF INDIANA UNIVERSITY
17386776 DIFFERENTIATION-INDUCED CELL POPULATION FROM WHICH UNDIFFERENTIATED CELLS HAVE BEEN REMOVED, USE OF SAME, AND METHOD FOR PRODUCING SAME Non-Final OA Osaka University
18624758 METHODS AND AGRICULTURAL COMPOSITIONS FOR PREVENTING OR CONTROLLING PLANT DISEASES Non-Final OA Bayer CropScience LP
17276267 METHODS OF CONTROLLING ANIMAL PESTS WITH PAENIBACILLUS TERRAE Non-Final OA Bayer CropScience LP
17055923 STABILIZED FUNGICIDAL COMPOSITION Final Rejection Bayer CropScience LP
18583042 METHYLOBACTERIUM COMPOSITIONS FOR FUNGAL DISEASE CONTROL Final Rejection NewLeaf Symbiotics, Inc.
17921802 COMPOSITIONS AND METHODS OF PROMOTING MYELINATION Non-Final OA The Children's Medical Center Corporation
18593295 DEVELOPMENT OF AN ACCELERATED CELLULAR MODEL FOR EARLY CHANGES IN ALZHEIMER’S DISEASE Non-Final OA University of Maryland, College Park
17514742 NON-INVASIVE METHODS FOR SELECTIVELY ENRICHING PLURIPOTENT CELLS Non-Final OA MEMORIAL SLOAN-KETTERING CANCER CENTER
18049327 NERVE CULTURE SYSTEM Non-Final OA Axogen Corporation
18187811 YEAST INHIBITION WITH BACILLUS SUBTILIS VIA IRON DEPLETION Final Rejection Chr. Hansen A/S
18286954 COMPOSITION CONTAINING MESENCHYMAL STEM CELL AND VASCULAR ENDOTHELIAL PROGENITOR CELL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OCCLUSIVE VASCULAR DISEASE OR COMPLICATION THEREOF Non-Final OA ELPHIS CELL THERAPEUTICS
18253076 METHODS OF STABLE VITRIFICATION Non-Final OA UPKARA, INC.
16827551 Seed Endophytes Across Cultivars and Species, Associated Compositions, and Methods of Use Thereof Final Rejection Indigo Ag, Inc.
18125963 SYSTEM AND METHODS FOR SOFT-TISSUE AUGMENTATION Non-Final OA NuVista, LLC
18044092 Treatment of Alzheimer's Disease with Allogeneic Mesenchymal Stem Cells Non-Final OA Longeveron, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month